Cauldron Ferm and QUT Drive Expansion in Australia's Precision Fermentation Landscape
Source: The DairyNews
In the latest updates from Australia's cellular agriculture sector, Cauldron Ferm and Queensland University of Technology (QUT) spearhead initiatives to establish a global framework for advancing precision fermentation production in the Asia-Pacific region.
Precision fermentation innovator, Cauldron Ferm, proudly announces the acquisition of a license from the Office of the Gene Technology Regulator (OGTR) to manufacture animal-free proteins at an impressive 10,000-liter scale.
Under the DIR200 license, Cauldron will deploy its exclusive hyper-fermentation technology and Pichia Pastoris yeast to generate proteins such as dairy, egg, and spider-silk. The thorough risk and management assessments conducted by OGTR, a part of the Australian Government's Department of Health and Aged Care, affirm the safety of Cauldron's hyper-fermentation process for the environment, staff, and community.
Michele Stansfield, CEO, and co-founder of Cauldron Ferm expresses, "This license significantly reduces the risk associated with Australian-based precision fermentation technologies and our proprietary hyper-fermentation process. It instills the confidence to swiftly establish fermentation facilities that promise significantly lower costs and a fraction of the capital expenditure."
Unlocking Precision Fermentation Ingredients
Established in 2022 by Stansfield in Orange, New South Wales, Cauldron asserts that its continuous fermentation platform outperforms conventional methods by producing ingredients five times more efficiently. Having secured AUD$10.5 million in funding last year for further scaling, the company envisions building the Asia-Pacific's most extensive network of precision fermentation facilities in regional Australia. This strategic move aims to leverage the nation's raw materials while contributing to job creation.
The newly acquired license empowers Cauldron to unleash large-scale capabilities in supplying animal-free proteins for both domestic and international markets. However, commercialization is contingent upon approval from Food Standards Australia New Zealand for any novel ingredient.
Stansfield adds, "Cauldron is pioneering as the first in Australia to hold a license of this nature at the 10,000-liter scale, unlocking production capabilities essential for the scaling efforts of all our local synthetic biology tech companies."
Under the DIR200 license, Cauldron will deploy its exclusive hyper-fermentation technology and Pichia Pastoris yeast to generate proteins such as dairy, egg, and spider-silk. The thorough risk and management assessments conducted by OGTR, a part of the Australian Government's Department of Health and Aged Care, affirm the safety of Cauldron's hyper-fermentation process for the environment, staff, and community.
Michele Stansfield, CEO, and co-founder of Cauldron Ferm expresses, "This license significantly reduces the risk associated with Australian-based precision fermentation technologies and our proprietary hyper-fermentation process. It instills the confidence to swiftly establish fermentation facilities that promise significantly lower costs and a fraction of the capital expenditure."
Unlocking Precision Fermentation Ingredients
Established in 2022 by Stansfield in Orange, New South Wales, Cauldron asserts that its continuous fermentation platform outperforms conventional methods by producing ingredients five times more efficiently. Having secured AUD$10.5 million in funding last year for further scaling, the company envisions building the Asia-Pacific's most extensive network of precision fermentation facilities in regional Australia. This strategic move aims to leverage the nation's raw materials while contributing to job creation.
The newly acquired license empowers Cauldron to unleash large-scale capabilities in supplying animal-free proteins for both domestic and international markets. However, commercialization is contingent upon approval from Food Standards Australia New Zealand for any novel ingredient.
Stansfield adds, "Cauldron is pioneering as the first in Australia to hold a license of this nature at the 10,000-liter scale, unlocking production capabilities essential for the scaling efforts of all our local synthetic biology tech companies."
